In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

[Q]: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious 24 disease localized to China, Japan, and Korea that is characterized by severe hemorrhage and a 25 high fatality rate. Currently, no specific vaccine or treatment has been approved for this 26 disease. To develop a therapeutic agent for SFTS, we isolated antibodies from a phage-27 displayed antibody library that was constructed from a patient who recovered from SFTS 28 virus (SFTSV) infection. One antibody, designated as Ab10, was reactive to the Gn envelope 29 glycoprotein of SFTSV and protected host cells and A129 mice from infection in both in 30 vitro and in vivo experiments. Notably, Ab10 protected 80% of mice, even when injected 5 31 days after inoculation with a lethal dose of SFTSV. Using cross-linker assisted mass 32 spectrometry and alanine scanning, we located the non-linear epitope of Ab10 on the Gn 33 glycoprotein domain II and an unstructured stem region, suggesting that Ab10 may inhibit a 34 conformational alteration that is critical for cell membrane fusion between the virus and host 35 cell. Ab10 reacted to recombinant Gn glycoprotein in Gangwon/Korea/2012, HB28, and SD4 36 strains. Additionally, based on its epitope, we predict that Ab10 binds the Gn glycoprotein in 37 247 of 272 reported SFTSV isolates previously reported. Together, these data suggest that 38 Ab10 has potential to be developed into a therapeutic agent that could protect against more 39 than 90% of reported SFTSV isolates. 40 41
[A]: An anti-Gn glycoprotein antibody from a convalescent patient potently 2 inhibits the infection of severe fever with thrombocytopenia syndrome virus

[Q]: Ability of CD8 + T cells to act as cytolytic effectors and produce IFN- was shown to mediate resistance to Toxoplasma gondii in murine models due to recognition of peptides restricted by murine MHC Class I molecules. However, no T. gondii specific HLA-B07 restricted peptides were proven protective against T gondii. Recently, two T gondii-specific HLA-B*0702-restricted T cell epitopes, GRA7 20-28 (LPQFATAAT) and GRA3 27-35 (VPFVVFLVA), displayed highaffinity binding to HLA-B*0702, and elicited IFN- from PBMCs of seropositive HLA-B*0702 persons. Herein, these peptides were evaluated to determine whether they could elicit IFN- in splenocytes of HLA-B*0702 transgenic mice when administered with adjuvants and protect against subsequent challenge. Peptide-specific IFN- producing T cells were identified by ELISPOT and proliferation assays utilizing splenic T lymphocytes from HLA transgenic mice. When HLA-B*0702 mice were immunized with one of the epitopes identified, GRA7 20-28 in conjunction with a universal CD4 + T cell epitope (PADRE) and adjuvants (CD4 + T cell adjuvant, GLA-SE, and TLR2 stimulatory Pam 2 Cys for CD8 + T cells), this immunization induced CD8 + T cells to produce IFN- and protected mice against high parasite burden when challenged with T gondii. This work demonstrates feasibility of bioinformatics followed by an empirical approach based on HLA binding to test this biological activity for identifying protective HLA-B*0702 restricted T gondii peptides and adjuvants that elicit protective immune responses in HLA-B*0702 mice.
[A]: Toxoplasma gondii HLA-B*0702 restricted GRA7 20-28 peptide with adjuvants and an universal helper T cell epitope elicits CD8 + T cells producing IFN- and reduces parasite burden in HLA- B*0702 mice 1 NIH Public Access

[Q]: Regulations are a part of life but who writes them, what is the basis on which they are written and when the regulations get it wrong, whose fault is it? Is it those who wrote the regulations, those enforcing the regulations, those being regulated or the science underpinning the regulations? In seeking answers to these questions, this paper explores the regulatory process and the contribution of science. It takes as examples the role of the Australian Pesticides and Veterinary Medicines Authority (APVMA) in regulating veterinary products, of the Security Sensitive Biological Agents regulations in managing the risks from specific pathogens, the Quarantine Act regulations as applied to containment facilities and the development of welfare standards. By dealing with products, pathogens, places and ''pets'' it provides a broad oversight of how regulations have been developed and applied from different perspectives and highlights the differing roles that science and research play both in developing policy and regulations. What is clear is that in the presence of good science it is usually possible to develop sound and defensible regulations e.g. those managed by APVMA, but when there is a lack of science to underpin the regulations, problems can arise e.g. in the case of animal welfare.
[A]:
Science delivering to regulators